Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of mbl in the preparation of drugs for preventing or treating effector T-cell-induced diseases

A cell and drug technology, applied to metabolic diseases, antibacterial drugs, drug combinations, etc., to achieve the effect of rich sources and strong regenerative ability

Active Publication Date: 2020-03-17
XINXIANG MEDICAL UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, whether there are still unknown factors that promote the inhibitory effect of Treg cells needs to be further developed and studied urgently

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of mbl in the preparation of drugs for preventing or treating effector T-cell-induced diseases
  • Application of mbl in the preparation of drugs for preventing or treating effector T-cell-induced diseases
  • Application of mbl in the preparation of drugs for preventing or treating effector T-cell-induced diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Experimental Materials

[0032] 1. The source of cells used in the experiment

[0033] Neonatal umbilical cord blood was collected from the Third Affiliated Hospital of Xinxiang Medical College and the Department of Obstetrics and Gynecology of Xinxiang First People's Hospital of full-term healthy newborns. Immediately after the fetus was delivered, blood was collected from the umbilical vein of the placenta and placed in a blood collection bag containing 28 mL of preservation solution. All blood samples were delivered to the laboratory within 4 hours after sampling.

[0034] 2. Main reagents

[0035] Medium RPMI1640, fetal bovine serum (FBS), and 10×PBS solution were all purchased from Thermo Fisher Scientific.

[0036] Lymphocyte separation medium (Ficoll-Paque PLUS), which is a sterile endotoxin (<0.12EU / mL) test solution of FicollTMPM400 and sodium diatrizoate with a density of 1.077g / mL, was purchased from GE Healthcare Life Sciences.

[0037] Anti-human CD3 mon...

Embodiment 2

[0094] Experimental Materials

[0095] 1. The source of cells used in the experiment

[0096] Reference example 1

[0097] 2. Main reagents

[0098] Reference example 1

[0099] 3. Main instruments and equipment

[0100] Reference example 1

[0101] 4. Preparation of common reagents

[0102] Reference example 1

[0103] experimental method

[0104] 1. Preparation of umbilical cord blood mononuclear cells

[0105] Reference example 1

[0106] 2. Coated with anti-CD3mAb

[0107] Reference example 1

[0108] 3. Magnetic separation of CD4+CD25-T cells and CD4+CD25+T cells

[0109] sample preparation

[0110] Peripheral mononuclear cells were separated by density gradient centrifugation. To remove platelets, cells were resuspended in buffer and centrifuged at 200×g for 10-15 min. The supernatant was carefully aspirated and washed repeatedly.

[0111] Magnetic labeling of non-CD4+ T cells

[0112] The whole process should be completed quickly, and the cells should be k...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
Login to View More

Abstract

The invention discloses the application of MBL in the preparation of drugs for preventing or treating effector T cell-induced diseases, and belongs to the technical field of new applications of mannan-binding lectins. The gist of the technical solution of the present invention is: the application of MBL in the preparation of drugs for the prevention or treatment of infectious diseases, autoimmune diseases or / and allergic diseases caused by effector T cells, wherein MBL inhibits the proliferation of effector T cells by enhancing iTreg cells achieve the efficacy of the drug. The present invention obtains the new factor that regulates Tregs cell inhibitory function through research, namely MBL directly strengthens Tregs cell to effector T cell proliferation inhibitory effect; The present invention highlights a kind of new function of MBL, not only plays an important anti-inflammatory role in innate immunity Infection, and in the intervention of Tregs cell function, it may be a target for the treatment of various autoimmune and inflammatory diseases.

Description

technical field [0001] The invention relates to the technical field of new applications of mannan-binding lectins, in particular to the application of MBL in the preparation of drugs for preventing or treating diseases induced by effector T cells. Background technique [0002] Mannose-binding lectin (mannan-binding lectin, MBL) is a highly conserved plasma protein mainly secreted by hepatocytes, and it is a member of the collectins family in the C-type lectin superfamily. MBL is also an acute phase response protein, and its plasma concentration can increase 2-3 times during stress (such as pathogen infection, surgery, etc.). MBL, known as ante-antibody, widely recognizes sugar structures distributed on the surface of various pathogens such as bacteria, viruses, parasites, fungi, etc., including D-mannose, through its carbohydrate recognition domain (CRD) Sugar, L-fucose, N-acetylglucosamine, N-acetylmannosamine, etc. Its collagen-like region (collagen-like region, CLR) com...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/36A61P33/02A61P33/06A61P31/04A61P31/22A61P31/18A61P1/16A61P31/20A61P31/14A61P37/02A61P3/10A61P29/00A61P19/02A61P17/00A61P5/16A61P17/14A61P37/08A61P11/02A61P11/06
CPCA61K38/36Y02A50/30
Inventor 王凡平王明永穆永慧张卫斌王帅杨帆吴敏娜陈晨段巨洪牛志国
Owner XINXIANG MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com